Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015899 · ClinicalTrials.gov registry record · Phase 1
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 9
- Study locations
NCT00015899: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Pediatric Brain Tumor Consortium.
NCT00015899 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 53 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (71% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00015899, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.
Conditions Studied
Interventions
- DRUG lonafarnib
Study Locations (9)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh - Pittsburgh
California
- UCSF Comprehensive Cancer Center - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
North Carolina
- Duke Comprehensive Cancer Center - Durham
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- Texas Children's Cancer Center - Houston
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2002-01 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
What the finished NCT00015899 record still lists
NCT00015899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which lonafarnib is the first listed.
NCT00015899 lists 9 locations in 8 states (Pennsylvania, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00015899 about?
NCT00015899 is a clinical study titled "SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors". RATIONALE: SCH 66336 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SCH 66336 in treating children with recurrent or progressive brain tumors.
What is the current status of trial NCT00015899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2002-01. Estimated completion is 2007-03.
What conditions does trial NCT00015899 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00015899?
The interventions under investigation include: lonafarnib (DRUG).
Who is sponsoring clinical trial NCT00015899?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015899 being conducted?
This trial has 9 study locations across California, District of Columbia, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00015899's enrollment target sits among peer trials
53 23rd of 45 higher than 23 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
-
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia